GSK Plans To Wield Aggressive Bolt-On Acquisition Strategy

GlaxoSmithKline is planning on moving aggressively beyond its core prescription drug business with possible bolt-ons in consumer health among other categories, CEO Andrew Witty told investors at a recent Goldman Sachs conference in New York